Moreover, the small molecular bromodomain and extraterminal domain (BET) inhibitors and the inhibitors of interleukin-2-inducible T-cell kinase (ITK) may become effective therapeutics for psoriasis based on different pathways [19,20]. This evidence concerns the gene ITK and psoriasis.